Your browser doesn't support javascript.
High Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence After the Third Epidemic Wave (May-October 2021) in Matadi, Democratic Republic of the Congo.
Munyeku-Bazitama, Yannick; Okitale-Talunda, Patient; Mpingabo-Ilunga, Patrick; Yambayamba, Marc K; Tshiminyi, Paul M; Umba-Phuati, Aimé; Kimfuta, Jacques; Phukuta, Ferdinand A; Makindu, Goethe; Mufwaya-Nsene, Raymond; Asari, Ryoko; Makimoto, Saeda; Baketana, Lionel K; Ahuka-Mundeke, Steve; Isono, Mitsuo; Nsio-Mbeta, Justus; Makiala-Mandanda, Sheila; Muyembe-Tamfum, Jean-Jacques.
  • Munyeku-Bazitama Y; Département de Virologie, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.
  • Okitale-Talunda P; Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Mpingabo-Ilunga P; Département de Biologie Médicale, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo.
  • Yambayamba MK; Département de Biologie Médicale, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo.
  • Tshiminyi PM; Département de Biologie Médicale, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo.
  • Umba-Phuati A; Département d'Epidémiologie et Biostatistiques, Ecole de Santé Publique, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo.
  • Kimfuta J; Département de Virologie, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.
  • Phukuta FA; Division Provinciale de Santé du Kongo Central, Matadi, Democratic Republic of the Congo.
  • Makindu G; Division Provinciale de Santé du Kongo Central, Matadi, Democratic Republic of the Congo.
  • Mufwaya-Nsene R; Division Provinciale de Santé du Kongo Central, Matadi, Democratic Republic of the Congo.
  • Asari R; Division Provinciale de Santé du Kongo Central, Matadi, Democratic Republic of the Congo.
  • Makimoto S; Japan International Cooperation Agency, Tokyo, Japan.
  • Baketana LK; Japan International Cooperation Agency, Tokyo, Japan.
  • Ahuka-Mundeke S; Japan International Cooperation Agency, Tokyo, Japan.
  • Isono M; Département de Virologie, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.
  • Nsio-Mbeta J; Département de Virologie, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.
  • Makiala-Mandanda S; Département de Biologie Médicale, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo.
  • Muyembe-Tamfum JJ; Japan International Cooperation Agency, Tokyo, Japan.
Open Forum Infect Dis ; 10(1): ofad023, 2023 Jan.
Article in English | MEDLINE | ID: covidwho-2222686
ABSTRACT

Background:

By the end of the third wave of the coronavirus disease 2019 (COVID-19) epidemic (May-October 2021), only 3130 of the 57 268 confirmed cases of coronavirus disease 2019 (COVID-19) in the Democratic Republic of the Congo (DRC) were reported in Kongo Central. This province, and especially its capital city, Matadi, has essential trade and exchanges with Kinshasa, the epicenter of the COVID-19 epidemic in DRC. Kinshasa accounted for 60.0% of all cases during the same period. The true burden of COVID-19 in Matadi is likely underestimated. In this study, we aimed to determine the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence and associated risk factors after the third wave in Matadi.

Methods:

We conducted a population-based cross-sectional study in October 2021. Consenting participants were interviewed and tested using an enzyme-linked immunosorbent assay commercial kit. We applied univariable and multivariable analysis to evaluate factors associated with seropositivity and adjusted the seroprevalence for the test kit performance.

Results:

We included 2210 participants from 489 households. Female participants represented 59.1%. The median age was 27 years (interquartile range, 16-45 years). The crude SARS-CoV-2 seroprevalence was 82.3%. Age was identified as the main risk factor as younger age decreased the seropositivity odds. Accounting for clustering at the household level increased the seroprevalence to 83.2%. The seroprevalence increased further to 88.1% (95% confidence interval, 86.2%-90.1%) after correcting for the laboratory test kit performance.

Conclusions:

The SARS-CoV-2 seroprevalence was very high, contrasting with reported cases. Evidence generated from this population-based survey remains relevant in guiding the local COVID-19 response, especially vaccination strategies.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: Open Forum Infect Dis Year: 2023 Document Type: Article Affiliation country: Ofid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: Open Forum Infect Dis Year: 2023 Document Type: Article Affiliation country: Ofid